Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients

Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients

Targeted therapy has been developed through an in-depth understanding of molecular pathways involved in the pathogenesis of melanoma. Approximately ~50% of patients with melanoma have tumors that harbor a mutation of the <i>BRAF</i> oncogene. Certain clinical features have been identifie...

Full description

Bibliographic Details
Main Authors: Sarah Zhou, Daniel Sikorski, Honghao Xu, Andrei Zubarev, May Chergui, François Lagacé, Wilson H. Miller, Margaret Redpath, Stephanie Ghazal, Marcus O. Butler, Teresa M. Petrella, Joël Claveau, Carolyn Nessim, Thomas G. Salopek, Robert Gniadecki, Ivan V. Litvinov
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
targeted therapy
reflex testing
<i>BRAF</i> inhibitor
<i>BRAF</i> mutation
MAPK pathway
metastatic melanoma
Online Access:https://www.mdpi.com/2072-6694/13/9/2282

Internet

https://www.mdpi.com/2072-6694/13/9/2282

Similar Items